ClinicalTrials.gg
WithdrawnNCT03789643RELIEF-PAHUpdated May 3, 2019

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

A Phase 2 interventional study of JTT-251 and Placebo in Pulmonary Arterial Hypertension, sponsored by Akros Pharma Inc.. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-05-03.

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Corporate decision, priority change

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)

Read the detailed description

This is a study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH). Participants completing this study (RELIEF-PAH) will be eligible to enroll in an open-label extension study (RELIEF-PAH OLE) to evaluate the long-term efficacy, safety, tolerability and pharmacokinetics of JTT-251 in participants with PAH.

02

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • JTT-251
  • Pulmonary arterial hypertension
  • RELIEF-PAH
  • Six-minute walk distance (6MWD)
03

In context

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

First submitted before Akros Pharma Inc. became part of Shionogi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PAH as classified by idiopathic, heritable, drug and toxin- induced, congenital heart disease or associated with connective tissue disease (i.e., WHO Group 1)
  • Clinical diagnosis of PAH confirmed by RHC at any time prior to Visit 1
  • WHO functional status of Class II-IV at Visit 1
  • Two 6MWD test measurements between 100 and 450 meters with a relative difference of ≤15%. The baseline 6MWD test must be performed at Visit 2 before randomization.
  • Have a qualifying RHC performed between Visit 1 and Visit 2
  • On stable dose(s) of guideline-directed medical therapy for PAH (endothelin receptor antagonists, phosphodiesterase type-5 (PDE-5) inhibitors, soluble guanylate cyclase stimulators and prostacyclin pathway analogs) for at least 90 days prior to the qualifying RHC

Exclusion criteria

Exclusion Criteria:

  • PAH associated with portal hypertension, (HIV), schistosomiasis or sickle cell disease as well as participants with pulmonary parenchymal disease or thromboembolic disease
  • Known significant left heart disease including: left ventricular dysfunction (i.e., \<35%); hemodynamically compromising, symptomatic, or severe aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation
  • Pulmonary hypertension belonging to WHO groups 2 to 5
  • Moderate to severe obstructive lung disease defined as (FEV1) \<55% of predicted value
  • Moderate to severe restrictive lung disease defined as total lung capacity (TLC) \<60% of predicted value
  • Acute decompensated heart failure or hospital admission for worsening PAH symptoms within 30 days prior to the qualifying RHC
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    JTT-251 Dose 1

    One dose of study drug by mouth daily for 24 weeks

    Drug: JTT-251

  • Experimental
    JTT-251 Dose 2

    One dose of study drug by mouth daily for 24 weeks

    Drug: JTT-251

  • Experimental
    JTT-251 Dose 3

    One dose of study drug by mouth daily for 24 weeks

    Drug: JTT-251

  • Placebo comparator
    Placebo

    One dose of study drug by mouth daily for 24 weeks

    Drug: Placebo

Interventions

  • DrugJTT-251

    Active drug tablets containing JTT-251

  • DrugPlacebo

    Placebo tablets matching in appearance to the active drug tablets

06

What researchers measure

Primary outcomes

  1. Change in six-minute walk distance (6MWD) compared to baseline

    Time frame: 24 Weeks

  2. Change in World Health Organization (WHO) functional classification compared to baseline

    Time frame: 24 Weeks

  3. Change in pulmonary vascular resistance (PVR) compared to baseline

    Assessed by right heart catheterization (RHC)

    Time frame: 4, 12, 24 and 28 Weeks

Secondary outcomes

  1. Number of adverse events

    Time frame: 28 Weeks

  2. JTT-251 trough plasma concentrations

    Time frame: 4, 12 and 24 Weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2019; primary completion for Mar 2021, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2018
First posted
Dec 28, 2018
StartEst.
Mar 2019
Primary completionEst.
Mar 2021
CompletionEst.
Jun 2021
Last update
May 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03789643
Lead sponsor
Akros Pharma Inc.
Responsible party
Sponsor
First posted
Dec 28, 2018
Start date
Mar 2019 (estimated)
Primary completion
Mar 2021 (estimated)
Completion
Jun 2021 (estimated)
Last update
May 3, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion